Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission.

Abstract excerpt

INTRODUCTION: Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most prevalent cause of familial and sporadic Parkinson's disease (PD). Because most pathogenic LRRK2 mutations result in enhanced kinase activity, it suggests that LRRK2 inhibitors may serve as a potential treatment for PD. To evaluate whether LRRK2 inhibitors are effective therapies for PD, it is crucial to know whether LRRK2 inhibitors...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aminopyridines
• Share to Benzamides
• Share to Biophysical Phenomena